Navigation Links
HPV Test Beats Pap Long-Term: Study
Date:7/31/2012

By Kathleen Doheny
HealthDay Reporter

MONDAY, July 30 (HealthDay News) -- Testing for HPV, the human papillomavirus linked to cervical cancer, can predict which women will stay cancer-free for a decade or more, a new study shows.

While both a positive HPV test and an abnormal result on a traditional Pap smear predicted which women would get precancerous lesions within two years of testing, the HPV test continued to predict which women were at risk for 10 to 18 years later, said study co-author Dr. Attila Lorincz, a professor of molecular epidemiology at Queen Mary University of London.

"HPV DNA testing detects more cervical precancers than the Pap test, and women who are negative for high-risk HPV DNA have improved protection from the risk of cervical cancer," Lorincz said.

The study, which looked at nearly 20,000 women receiving routine Pap tests and HPV testing at Kaiser Permanente in Portland, Ore., is published in the July 30 issue of the Journal of Clinical Oncology.

The research does not suggest one test should replace the other, Lorincz stressed, but confirms the importance of both screenings. The main aims of the study, he said, "were to see how many extra cases of precancer can be discovered by the additional use of HPV DNA testing as compared to routine Pap testing."

The findings, he said, support recently revised guidelines suggesting that HPV testing, if negative, can allow for longer intervals between Pap testing for women over the age of 30. The findings also suggest that an alternate strategy, using HPV testing first, may work well, the researchers said.

According to American Cancer Society guidelines, the preferred screening for healthy women aged 30 to 65 is to do a Pap and HPV test every five years. Women under 30 are often infected with HPV, but clear it spontaneously. That is why the guidelines for the roles of HPV and Pap testing combined are for women aged 30 and older.

As more research is done, guidelines may change, said study co-author Dr. Andrew Glass, senior investigator at Kaiser Permanente Center for Health Research. "It is likely that HPV testing will be more and more common and may in the future replace routine Pap testing," he said.

Both the Pap test and the HPV test are done on samples of cells taken from the cervix. The Pap detects cell changes on the cervix that could become cancer if not treated appropriately.

HPV tests look for DNA, or genetic material, of the virus that can lead to precancerous changes.

In the study, women over 30 with a positive HPV at the start were more likely to have a precancer or cancer during the 10- to 18-year follow-up than those who had an abnormal Pap.

Women who tested positive for the two strains of HPV most strongly linked with cervical cancer were more likely to have precancer during the follow-up than HPV-negative women, regardless of their initial Pap test result.

Having a negative HPV more strongly predicted who would remain cancer-free than the Pap did, the investigators found.

The researchers also looked at the effect of lengthening the screening interval from three years to five in women over 30 who had negative HPV and normal Pap tests. Doing this did not increase the risk of precancer and cancers appreciably.

Both tests are commonly covered by insurance plans, sometimes requiring a co-payment. The typical cost for each test is about $40 to $70, according to Lorincz.

The study finding "confirms the fact that you don't have to do a Pap smear every year in healthy women over 30," said Dr. Mark Wakabayashi, director of the division of gynecologic oncology at the City of Hope, in Duarte, Calif.

However, he stressed the importance of checking in with a doctor. "But you have to talk to someone who understands who does need a yearly Pap," he said. "This [finding] applies just to healthy women."

The findings have nothing to do with whether you received the HPV vaccine or not, Wakabayashi said. "A lot of people are thinking if they had the vaccine they don't need a Pap smear. Not true," he said. While the HPV vaccine aims to protect against cervical cancer, screenings are still crucial.

Study leader Dr. Philip Castle, of the American Society for Clinical Pathology, does consultant work for Merck, which makes an HPV vaccine. Lorincz is a consultant for, and owns stock in, Qiagen, which makes HPV tests.

More information

To learn more about screening for cervical cancer, visit the U.S. Centers for Disease Control and Prevention.

SOURCES: Mark Wakabayashi, M.D., director, division of gynecologic oncology, City of Hope, Duarte, Calif.; Attila Lorincz, Ph.D., professor, molecular epidemiology, Queen Mary University of London; Andrew Glass, M.D., senior investigator, Kaiser Permanente Center for Health Research, Portland, Ore.; July 30, 2012, Journal of Clinical Oncology


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Medicare Beats Private Plans for Patient Satisfaction: Survey
2. Coordinated Care Boosts Cardiac Arrest Survival: Study
3. Abandoning PSA Screening Could Cost Lives: Study
4. Women and Children First? Not So, Says Study
5. Alcohol Is a Social Lubricant, Study Confirms
6. Booze, Energy Drinks, Casual Sex Combo Common in College: Study
7. Health coaches could be key to successful weight loss, study suggests
8. Most Prostate Cancer Patients Dont Die From the Disease: Study
9. Childbirth After 30 Lowers Risk of Endometrial Cancer: Study
10. Landmark HIV treatment-as-prevention study shows additional health benefits, cost-effectiveness
11. Study finds novel therapy that may prevent damage to the retina in diabetic eye diseases
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
HPV Test Beats Pap Long-Term: Study
(Date:12/2/2016)... Raleigh, NC (PRWEB) , ... December 02, 2016 , ... ... the Open Enrollment Period (or Annual Election Period), is ending December 7th. Currently-enrolled Medicare ... plan (Part C) or prescription drug plan (Part D) need to make changes during ...
(Date:12/2/2016)... New York, NY (PRWEB) , ... December 02, ... ... today, featuring an inspirational interview of two ostomy patients, standing as living proof ... million people suffer from digestive diseases and issues that spike around the holidays. ...
(Date:12/2/2016)... ... December 02, 2016 , ... Mediaplanet ... in USA Today, which covers the innovative treatments, therapeutic technologies, and revolutionized nutrition ... lives. “We are prolonging life 6 years in the last 3 decades,” says ...
(Date:12/2/2016)... ... 02, 2016 , ... Universal Medical Systems, Inc. (UMS) the ... company to offer robotic imaging to veterinary medicine is sponsoring the appearance of ... the American Association of Equine Practitioners 62nd Annual Convention from December 4-6, 2016 ...
(Date:12/2/2016)... , ... December 02, 2016 , ... Yisrayl Hawkins, at ... into how this current generation fits into Bible Prophecy. Yisrayl says this generation, known ... pointing to this conclusion, showing how the details line up exactly with Bible Prophecy ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)...  PipelineRx, a leading medication management technology company ... of its SaaS-based telepharmacy platform, PowerGridRx™ , ... Midyear Clinical Meeting and Exhibition, December 5-7 in ... 300 hospital clients nationally, the Company is a ... dramatically improve pharmacy operations, enhance patient safety, and ...
(Date:12/2/2016)... 2016  Maxor National Pharmacy Services, LLC ("Maxor"), today announced ... ("PSI").  The combination of Texas -based Maxor ... PSI bring together both company,s clinical expertise and high-touch patient ... industry-leading specialty pharmacy. About Maxor ... , , ...
(Date:12/2/2016)... 2, 2016 Lianluo Smart Limited (Nasdaq: ... Company") which develops, markets and sells medical devices ... China and international markets, recently attended ... Treatment New Progress Forum, co-hosted by the Institute ... , Guangdong Provincial People,s Hospital and Cardiology ...
Breaking Medicine Technology: